Interpace Biosciences

Interpace Biosciences EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of Interpace Biosciences (IDXG) as of Nov 19, 2026 is 2.01. In the previous year, EV/EBIT (Enterprise Value to EBIT) was 1.01 — a change of 98.53% (higher).

EV/EBIT

2.01

YoY

98.53%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Interpace Biosciences is 2025 2.01 . EV/EBIT (Enterprise Value to EBIT) of Interpace Biosciences was 2024 1.01 . It decreases by 98.53% higher compared to the previous year.

The Interpace Biosciences EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBIT
Date
EV/EBIT
Jan 1, 2018
-0.69 USD
Jan 1, 2019
-0.31 USD
Jan 1, 2020
-0.32 USD
Jan 1, 2021
-0.57 USD
Jan 1, 2022
-2.13 USD
Jan 1, 2023
2.07 USD
Jan 1, 2024
1.01 USD
Jan 1, 2025
2.01 USD
The Interpace Biosciences EV/EBIT history
YEAREV/EBITYoY
2.01+98.53%
1.01-51.12%
2.07-196.90%
-2.13+277.42%
-0.57+76.63%
-0.32+2.50%
-0.31-54.82%
-0.69-46.92%
-1.30+2.37%
-1.27+527.26%
-0.20-66.67%
-0.61—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Interpace Biosciences Valuation

Details

Historical Valuation Multiples

ⓘ

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Interpace Biosciences's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Interpace Biosciences's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Interpace Biosciences's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Interpace Biosciences grows earnings faster than its peers.

Interpace Biosciences Stock analysis

What does Interpace Biosciences do? Interpace Biosciences develops and sells diagnostic clinical and pharma services, focusing on molecular tests for cancer risk evaluation. The company offers five commercialized tests: PancraGEN for pancreatic cancer diagnosis from cysts, PanDNA as a molecular snapshot of limited factors, ThyGeNEXT for thyroid cancer diagnosis using sequencing, ThyraMIR v2 used with ThyGeNEXT for thyroid cancer, and RespriDX to differentiate lung cancer origins. These products are sold to healthcare providers and laboratories seeking advanced diagnostic solutions for cancer risk assessment and treatment planning. Interpace Diagnostics, the company's division, provides bioinformatics and pathology services alongside its molecular tests. The tests target specific cancer types, with PancraGEN and PanDNA addressing pancreatic cancer, ThyGeNEXT and ThyraMIR v2 for thyroid cancer, and RespriDX for lung cancer differentiation. Healthcare institutions and physicians utilize these services to improve diagnostic accuracy and patient outcomes in oncology care. The company's revenue streams come from the direct sale of its molecular diagnostic tests and associated services to medical professionals and healthcare facilities. These services are positioned for precision medicine applications, supporting cancer diagnosis, prognosis, and treatment decisions. The business model relies on the clinical utility and technological innovation of its tests to drive adoption among healthcare providers focused on oncology diagnostics. Interpace Biosciences is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Interpace Biosciences stock

EV/EBIT (Enterprise Value to EBIT) of Interpace Biosciences is 2.01 in 2025.

EV/EBIT (Enterprise Value to EBIT) of Interpace Biosciences changed from 1.01 to 2.01, representing a 98.53% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) Interpace Biosciences since 2006 – with annual values, charts, and detailed analysis.

The EV/EBIT ratio measures a company's enterprise value relative to its operating earnings. It accounts for debt, making it useful for comparing companies with different capital structures.

EV/EBIT = Enterprise Value / Earnings Before Interest and Taxes

To evaluate EV/EBIT (Enterprise Value to EBIT)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBIT (Enterprise Value to EBIT).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBIT (Enterprise Value to EBIT)'s Interpace Biosciences with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Interpace Biosciences

All Key Metrics — Interpace Biosciences